Statin use and pain in older people with cancer: A cross-sectional study

Journal of the American Geriatrics Society

Volumn 62, Issue 10, 2014, Pages 1900-1905

  Turner, Justin P ^a,b,c   Shakib, Sepehr ^c   Singhal, Nimit ^c,d   Hogan Doran, Jonathon ^c   Prowse, Robert ^c   Johns, Sally ^c   Thynne, Tilenka ^e   Bell, J Simon ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e FLINDERS UNIVERSITY   (Australia)

Author keywords

aged; aged 80 and older; deprescribe; geriatric oncology; HMG CoA; statins

Indexed keywords

ANALGESIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NARCOTIC ANALGESIC AGENT;

AGED; ARTHRITIS; ARTICLE; BREAST CANCER; CANCER PAIN; CANCER PALLIATIVE THERAPY; CHARLSON COMORBIDITY INDEX; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIGESTIVE SYSTEM CANCER; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NEOPLASM; PAIN ASSESSMENT; PAIN INTENSITY; PRIMARY PREVENTION; PROSTATE CANCER; SELF CONCEPT; VISUAL ANALOG SCALE; AUSTRALIA; EPIDEMIOLOGY; NEOPLASMS; PAIN; PALLIATIVE THERAPY; SECONDARY PREVENTION; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AUSTRALIA; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; NEOPLASMS; PAIN; PALLIATIVE CARE; PRIMARY PREVENTION; SECONDARY PREVENTION; VISUAL ANALOG SCALE;

EID: 84911953502     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/jgs.13051     Document Type: Article

References (30)

1. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
2. Afilalo J, Duque G, Steele R, et al. Statins for secondary prevention in elderly patients: A hierarchical Bayesian meta-analysis. J Am Coll Cardiol 2008; 51: 37-45.
3. National Center for Health S. Health, United States. Health, United States, 2010: With Special Feature on Death and Dying. Hyattsville, MD: National Center for Health Statistics, 2011.
4. Hilmer SN, Gnjidic D, Le Couteur DG,. Thinking through the medication list-appropriate prescribing and deprescribing in robust and frail older patients. Aust Fam Physician 2012; 41: 924-928.
5. Chokshi NP, Messerli FH, Sutin D, et al. Appropriateness of statins in patients aged >/=80 years and comparison to other age groups. Am J Cardiol 2012; 110: 1477-1481.
6. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 129 (25 Suppl 2): S1-S45.
7. Petersen LK, Christensen K, Kragstrup J,. Lipid-lowering treatment to the end? A review of observational studies and RCTs on cholesterol and mortality in 80 + -year olds. Age Ageing 2010; 39: 674-680.
8. Dobkin BH,. Underappreciated statin-induced myopathic weakness causes disability. Neurorehabil Neural Repair 2005; 19: 259-263.
9. Mansi I, Frei CR, Pugh MJ, et al. Statins and musculoskeletal conditions, arthropathies, and injuries. JAMA Intern Med 2013; 173: 1-10.
10. Buettner C, Davis RB, Leveille SG, et al. Prevalence of musculoskeletal pain and statin use. J Gen Intern Med 2008; 23: 1182-1186.
11. Evans MA, Golomb BA,. Statin-associated adverse cognitive effects: Survey results from 171 patients. Pharmacotherapy 2009; 29: 800-811.
12. Hippisley-Cox J, Coupland C,. Unintended effects of statins in men and women in England and Wales: Population based cohort study using the QResearch database. BMJ 2010 May 20; 340: c2197. doi: 10.1136/bmj.c2197
13. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735-742.
14. Riechelmann RP, Krzyzanowska MK, Zimmermann C,. Futile medication use in terminally ill cancer patients. Support Care Cancer 2009; 17: 745-748.
15. Stavrou EP, Buckley N, Olivier J, et al. Discontinuation of statin therapy in older people: Does a cancer diagnosis make a difference? An observational cohort study using data linkage BMJ Open 2012; 2: Pii-e000880.
16. Turner JP, Shakib S, Singhal N, et al. Prevalence and factors associated with polypharmacy in older people with cancer. Support Care Cancer 2014; 22: 1727-1734.
17. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987; 40: 373-383.
18. Lees J, Toh B,. Does a pharmacist derived medication history (MH) provide more information than a geriatric cancer patient-completed medication list, and does it matter? Asia Pac J Clin Oncol 2009; 5 (Suppl 2): A176.
19. Lau HS, Florax C, Porsius AJ, et al. The completeness of medication histories in hospital medical records of patients admitted to general internal medicine wards. Br J Clin Pharmacol 2001; 49: 597-603.
20. World Health Organization. Guidelines for ATC Classification and DDD Assignment, 2012. Oslo: World Health Organization, 2011.
21. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, et al. Prevalence of pain in patients with cancer: A systematic review of the past 40 years. Ann Oncol 2007; 18: 1437-1449.
22. Serlin RC, Mendoza TR, Nakamura Y, et al. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 1995; 61: 277-284.
23. Li KK, Harris K, Hadi S, et al. What should be the optimal cut points for mild, moderate, and severe pain? J Palliat Med 2007; 10: 1338-1346.
24. Steinhauser KE, Christakis NA, Clipp EC, et al. Factors considered important at the end of life by patients, family, physicians, and other care providers. JAMA 2000; 284: 2476-2482.
25. Wargo JJ, Northouse LL, Schafenacker AM, et al. Lack of discontinuation of statin therapy after diagnosis of end-stage cancer. Contemp Oncol 2013; 1: 1.
26. Silveira MJ, Kazanis AS, Shevrin MP,. Statins in the last six months of life: A recognizable, life-limiting condition does not decrease their use. J Palliat Med 2008; 11: 685-693.
27. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther 2005; 19: 403-414.
28. Franc S, Dejager S, Bruckert E, et al. A comprehensive description of muscle symptoms associated with lipid-lowering drugs. Cardiovasc Drugs Ther 2003; 17: 459-465.
29. Vollrath AM, Sinclair C, Hallenbeck J,. Discontinuing cardiovascular medications at the end of life: Lipid-lowering agents. J Palliat Med 2005; 8: 876-881.
30. Fried TR, Tinetti ME, Towle V, et al. Effects of benefits and harms on older persons' willingness to take medication for primary cardiovascular prevention. Arch Intern Med 2011; 171: 923-928.